A. Bikov (Miskolc, Hungary), R. Gosens (Groningen, Netherlands)
Quantification and treatment patterns of real-world patients classified by the GOLD 2011 strategy
M. Small, S. Broomfield, V. Higgins (Macclesfield, United Kingdom)
|   |
Differential dropout may affect exacerbation risk estimates differently in moderate-to-very severe COPD
P. Calverley, G. Eriksson, D. Postma, C. Jenkins, A. Anzueto, B. Make, A. Persson, M. Fagerås, T. Similowski (Liverpool, United Kingdom; Lund, Mölndal, Sweden; Groningen, Netherlands; Camperdown, Australia; San Antonio, Denver, United States Of America; Paris, France)
| |
A randomized, crossover study to examine the pharmacodynamics and safety of a new antimuscarinic (TD-4208) in COPD
P. Potgieter, A. Hopkins, P. Liu, D. Quinn, C. Amburgey, E. Moran (San Francisco, United States Of America; Wellington, New Zealand)
| |
Association of β2-adrenoreceptor genotypes with prevention of COPD exacerbations by tiotropium or salmeterol in the POET-COPD® trial
H. Koegler, K.F. Rabe, K.M. Beeh, T. Glaab, H. Schmidt, L.M. Fabbri, C. Vogelmeier (Ingelheim, Grosshandorf, Wiesbaden, Marburg, Germany; Modena, Italy)
| |
Effects of high dose N-acetylcysteine in COPD patients
W. De Backer, C. Van Holsbeke, A. Sadowska, J. De Backer, R. Claes, W. Vos (Kontich, Edegem, Belgium)
| |
Acute effect of erdosteine on preventing recurrence of exacerbation in COPD patients after hospital discharge
M. Moretti, M. Ballabio (Carrara, Paderno Dugnano, Italy)
| |
Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD
R. Aalbers, M.R. Maleki-Yazdi, A. Hamilton, S. Waitere-Wijker, A. Pivovarova, O. Schmidt, L. Bjermer (Groningen, Alkmaar, Netherlands; Ontario, Canada; Biberach, Koblenz, Germany; Lund, Sweden)
| |
Anti-inflammatory effects of add-on atorvastatin therapy during the treatment of COPD patients
R. Mroz, A. Tycinska, P. Lisowski, J. Bierla, L. Minarowski, R. Milewski, A. Lisowska, P. Boros, E. Chyczewska, W. MacNee (Bialystok, , Jastrzebiec, Warsaw, Poland; Edinburgh, United Kingdom)
| |
An audit of oxygen prescribing practices in a district general hospital
A. Szulc, R. Berry, S.F. Hussain (Leicester, Kettering, United Kingdom)
| |
Once-daily NVA237 reduces exacerbations and improves symptoms in COPD patients: A pooled analysis of the GLOW1 and GLOW2 studies
D. Banerji, V. Alagappan, C. Martin, E. He, H. Chen, T. Overend (East Hanover, United States Of America; Horsham, United Kingdom)
| |
Cigarette smoke retention and bronchodilation in patients with COPD: A controlled randomized trial
W. van Dijk, Y. Heijdra, J. Lenders, W. Klerx, R. Akkermans, A. van der Pouw, C. van Weel, P. Scheepers, T. Schermer (Nijmegen, Eindhoven, Arnhem, Netherlands; Dresden, Germany)
| |
Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: Mid-high dose assessment
F. Martinez, J. Boscia, G. Feldman, C. Scott-Wilson, S. Kilbride, L. Fabbri, P.M.A. Calverley, C. Crim (Ann Arbor, Union, Spartanburg, Research Triangle Park, United States Of America; Modena, Italy; Liverpool, United Kingdom)
| |
Efficacy of the novel inhaled corticosteroid, fluticasone furoate (FF)/long-acting beta2-agonist, vilanterol (VI) combination in reducing COPD exacerbations
M.T. Dransfield, P.M.A. Calverley, J. Bourbeau, P. Jones, N.A. Hanania, D.A. Mahler, J. Vestbo, A. Wachtel, F. Martinez, F. Barnhart, L. Sanford, S. Lettis, C.C. Crim (Birmingham, Houston, Hanover, Ann Arbor, Research Triangle Park, United States Of America; Liverpool, London, Manchester, Uxbridge, United Kingdom; Montreal, Canada)
| |
Efficacy of combination fluticasone furoate/vilanterol (FF/VI) and salmeterol/fluticasone propionate (SFC) over 12 weeks in patients with COPD
A. Agusti, W. De Backer, L. de Teresa, M. Zvarich, N. Locantore, N. Barnes, J. Bourbeau, C. Crim (Alicante, Spain; Wilrijk, Belgium; Research Triangle Park, United States Of America; London, United Kingdom; Montreal, Canada)
| |
Effects of twice-daily aclidinium bromide in COPD patients: A long-term extension of ACCORD-COPD I
A. D‘Urzo, E. Kerwin, J. Donohue, S. Rennard, A. Gelb, H. Lakkis, E. Garcia Gil, C. Caracta (Toronto, Canada; Medford, Chapel Hill, Omaha, Lakewood, Jersey City, United States Of America; Barcelona, Spain)
| |
Pooled analysis of twice-daily aclidinium bromide in COPD patients: Dyspnea and health status in the ACCORD-COPD I and ATTAIN trials
P. Jones, E. Kerwin, E. Bateman, R. Lamarca, C. Caracta, E. Garcia Gil (London, United Kingdom; Medford, Jersey City, United States Of America; Cape Town, South Africa; Barcelona, Spain)
| |
Twice-daily aclidinium bromide in COPD patients: A pooled analysis of lung function in the ACCORD-COPD I and ATTAIN trials
E. Kerwin, P. Jones, A. D‘Urzo, L. Rekeda, E. Garcia Gil, C. Caracta (Medford, Jersey City, United States Of America; London, United Kingdom; Toronto, Canada; Barcelona, Spain)
| |
Long-term efficacy of twice-daily aclidinium bromide in COPD patients: A one-year study
D. Tashkin, A. Gelb, B. Make, X. Zhong, E. Garcia Gil, C. Caracta (Los Angeles, Lakewood, Denver, Jersey City, United States Of America; Barcelona, Spain)
| |